Rare 100% response rate a shot in the arm for cancer research
Members of the West Cancer Center & Research Instituter team assist a patient who participated in a clinical trial focused on malignant skin and soft tissue cancers. The trial resulted in a 100% response rate, meaning the treated tumors completely disappeared in 12 weeks, and with no adverse events. (Courtesy West Cancer Center & Research Institute)
West Cancer Center & Research Institute recently completed a clinical trial that eliminated treated tumors in 12 weeks without adverse effects.
Topics
West Clinic cancer research Dr. Noam VanderWalde clinical trial Subscriber Only alpha dart alpha tau medicalThank you for being a subscriber to The Daily Memphian. Your support is critical.
As a 501(c)3 nonprofit news organization with a hybrid business model, we rely on a mix of revenue from subscriptions (50%), advertising, events and miscellaneous earned income (25%) and fundraising (25%).
Please consider making a fully tax-deductible donation or other contribution to The Daily Memphian today.
👉 Your subscription pays for you to read all our journalism.
👉 Your donation powers the work we do to reach everyone else with the news.
We believe an informed Memphis is a better Memphis. If you agree, join our growing list of donors now.
Aisling Mäki
Aisling Mäki covers health care, banking and finance, technology and professions. After launching her career in news two decades ago, she worked in public relations for almost a decade before returning to journalism in 2022.
As a health care reporter, she’s collaborated with The Carter Center, earned awards from the Associated Press and Society of Professional Journalists and won a 2024 Tennessee Press Association first-place prize for her series on discrepancies in Shelby County life expectancy by ZIP code.
Comments
Want to comment on our stories or respond to others? Join the conversation by subscribing now. Only paid subscribers can add their thoughts or upvote/downvote comments. Our commenting policy can be viewed here.